Try our Advanced Search for more refined results
Life Sciences - July, 2017
342 articles
- Dr. Oz-Backed Cos. Can't Escape Suit Over Diet Pills
- SEC Fines Brokerage Firm, Restricts Penny Stock Deposits
- Calistoga Tells Del. Justices Gilead Owes $50M Drug Bonus
- LabCorp. Drops $1.2B To Buy Research Contractor Chiltern
- Deals Rumor Mill: Dow, Fosun Pharmaceutical, Anbang
- Congressional Forecast: August
- T. Rowe, Funds Fight Valeant's Bid To Kill Stock Drop Suits
- Epstein Becker Green Hires FDA Regulatory Lawyer
- Genetic Privacy Row Beats Dismissal Bid Without Class Cert.
- Board-Suspicious Biotech Investors Sue For Records
- Investors Sue Abuse-Deterrent Opioid Co. After FDA Setback
- If The Surgeon's A Robot, Who's The Learned Intermediary?
- Cybersecurity Risks In The Courtroom
- J&J Presses Expert On Talc Studies In Calif. Cancer Trial
- Attys Predict Next Steps After ACA Repeal Failure
- Only 1 Suit Left In Eliquis MDL As 20 More Cases Get Cut
- Shkreli Called A 'Con Man' As Fraud Case Heads To Jury
- PTAB To Review 3 Herceptin Patents In Hospira Challenge
- Health Hires: EBG, Buchalter, Reproductive Rights Center
- Gilead Says Macleods India Infringed HIV Medication Patents
- Families In Zofran MDL Seek Docs About Foreign Regulators
- NJ Appeals Court Revives 2K Cases In Accutane Litigation
- Gray Matters: Clients Are Not Really 'Emotional'
- Sanofi Asks To Go Solo With Its EpiPen Fight Against Mylan
- Colgate Retirees Get Class Cert. In Denied Benefits Row
- Feds Call Shkreli A Liar As Defense Denies Any Fraud
- Del. Vice Chancellor Presses Innoviva On Proxy Deal Drop
- Talc Is Toxic, Expert Says In First Calif. J&J Cancer Trial
- Access To Branded Drug Samples Key To Generics, Reps Hear
- Millennium Labs Judge Grills Sides On 3rd-Party Releases
- Fed. Circ. Affirms PTAB Nix Of Soft Gel Patents
- Fed. Circ. OKs Inequitable Conduct Ruling Against Regeneron
- BioScrip Investors' Attys Win $2.7M In Fees From $11M Deal
- DNA Co., Mother Resolve Baby Sex Test Dispute
- Ex-Insys Execs, Prosecutors Spar Over Patient 'Victims'
- FDA Panel Recommends Against OK'ing Blue-Dye Opioid
- Vet Products Co. Not Covered For TCPA Suit, Judge Rules
- Coca-Cola, Others Must Face Superfund Suit, Ohio Judge Told
- Avoiding The Rotten Compromise In Mass Litigation
- Having A Chief Privacy Officer Reassures Your Firm's Clients
- J&J Hid Talc Cancer Risk To Save Image, Calif. Jury Told
- J&J, DePuy To Face Partly Revived FCA Suit Over Hip Device
- Global Cartel Fines Down In 2017, Report Says
- PTAB Won't Review AstraZeneca's Symbicort Inhaler Patent
- Deals Rumor Mill: JPMorgan, Nature's Bounty, Snapdeal
- Shkreli Loses Bid To Nix Charges After Resting Case
- J&J Wants 5th Circ. To Block Fourth Hip Implant Bellwether
- UC Urges Fed. Circ. To Nix 'Unjust' Gene Editing Patent Ruling
- IRS Brings Transfer Pricing Row With Medtronic To 8th Circ.
- J&J Can't Beat Andover False Ad Suit Over Bandages
- Cancer-Drug Maker Loses 2nd Bid To Duck Stock-Drop Suit
- FDA Raises Safety Concerns With Hep B Vaccine
- ACA Repeal: Deciphering The Path Ahead
- The 9th Circ.'s Expansive Reading Of Escobar In Gilead
- Innovating For Wise Juries: Discussions Before Deliberations
- Combating Securities Fraud Allegations With 10b5-1 Plans
- Altor Bioscience Investors Fail To Halt $290M NantCell Merger
- Shkreli Slams Katten Atty In Emails, As Trial Wraps Up
- FDA Warning Wire: Cancer-Treating Claims On Christian Site
- Accutane Label Didn't Adequately Warn, NJ Panel Says
- Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit
- Pa. Appeals Court Asked To Lift Cap On Risperdal Damages
- Olympus To Pay $6.6M Over Role In Patient's Deadly Infection
- Ex-Adviser Cops To Trading Scheme With Ex-Hunton Atty
- BakerHostetler Nabs Thompson Hine Life Sciences Patent Atty
- Paul Hastings Atty Joins Latham's White Collar Team
- $5B Parexel Take-Private Deal Incites Investors
- Judge Reverses J&J's Win In Philly Pelvic Mesh Mass Tort
- GOP Narrowly Starts Debate On ACA Repeal
- Stada Boards Back Sweetened €4.12B Bain, Cinven Buyout
- Holland & Knight Adds IP Attorney From Cantor Coburn
- Retailers Seek Docs Given To FTC In Aggrenox MDL
- 5 Questions Firms Should Ask When Evaluating Litigation AFA
- For Law Firm Offices, Business Savvy Is The New Cool
- SEC Wins Bid To Shield Notes From Atty Gone Fraudster
- Democrats Launch New Campaign To Target Rx Drug Costs
- 11 Teva Entities Can't Escape Pa. Generic Price-Fixing Suit
- Dems Embark On Agenda To Limit Mergers, Tax Loopholes
- Merck Launches 2nd Biosimilar Rival To J&J's Remicade
- Janssen, Bayer Must Face Third Bellwether In Xarelto MDL
- Philips Says It's Owed $217M In Defibrillator Patent Row
- Shkreli Says He Won't Take Stand At Securities Fraud Trial
- Mesh Cases Against Boston Scientific Withdrawn From Philly
- Mitsubishi Tanabe Pays $1.1B For Israeli Clinical Drug Co.
- FDA Staff Flags Lack Of Data On Abuse Potential For Opioid
- BPCIA Questions Continue To Arise For Biosimilar Applicants
- AbbVie Must Pay $150M For False AndroGel Ads, Jury Says
- Endologix Seeks Sanctions For Investor's Witness Statements
- The Best Documents In Your Case May Be From 3rd Parties
- Planning A Legal Career With A Future Relocation In Mind
- The Best Law Firms For Female Partners
- The Best Law Firms For Female Attorneys
- How 4 Firms Are Moving The Needle On Gender Diversity
- 4 Female Perspectives On BigLaw Leadership
- Could An NFL Diversity Rule Be A BigLaw Game-Changer?
- BigLaw Bias Suits New Wild Card In Fight For Gender Equity
- Women See Another Year Of Slow Gains At Law Firms
- 7th Circ. Sides With Immigrant In Row Over Marijuana Offense
- Feds' Shkreli Case Nears End, Amid Testy Exchanges
- Jury Begins Deliberations In Suit Over AbbVie's AndroGel
- Hormone Clinic Chain Must Pay $18M Over Safety Claims
- FDA's E-Cig Rule Survives Industry Challenge
- Texas Judge Questions Arbitration For 'Indirect Customers'
- Calif. Nutrition Co. Takes Row Over Wash. Tax To High Court
- Key ACA Repeal Elements Need 60 Votes
- Cherokee Nation Says Opioid Dispute Belongs In Tribal Court
- Drug Info Co. Wants Defense In Bayer's Price Listing Suit
- Illumina, Qiagen Settle DNA Sequencer Patent Dispute
- WilmerHale Must Face 'Freeze-Out' Suit, Appeals Court Says
- Hogan Lovells Snags Veteran HHS, FDA Attorney
- The Elephant In The Room: Advancing Women To Partnership
- How Midsize Law Firms Can Minimize Cybersecurity Threats
- Judge Mulls Privacy Concerns In Utah Drug Records Case
- Ex-ArthroCare CEO Can't Escape Wire Fraud Charges
- Bayer Says 'Flanax' Antitrust Counterclaims Ignore Market
- Pharma Co. Fails In DQ Bid Against Ex-CEO's Counsel
- Amphastar Escapes $1B Momenta, Sandoz Infringement Suit
- High Court Signals Interest In Vitamin C Price-Fix Case
- Is Bankruptcy An Option For Ancillary Marijuana Businesses?
- Jurors Won't Hear Theory J&J Conspired To Hide Talc Danger
- Shkreli, Gov't Embroiled In Investor Evidence Fight
- PTAB Upholds Validity Of 5 Patents For Pfizer's Toviaz
- Amphastar Asks Jury To Nix $1B Momenta Infringement Case
- Study Says Some Antibiotics Up Risk Of Birth Defects
- Greatbatch, AVX Argue Final Details Ahead Of Patent Trial
- Drug, Device Cos. Assail FDA's Off-Label Stance
- FTC Balks At Discovery Extension In AndroGel Antitrust Suit
- Abbott, Fla. Pharmacy Settle 'Gray Market' Test Strip Suit
- Namenda Buyers' Experts Should Stay, Judge Says
- FDA Tentatively OKs Merck Biosimilar To Sanofi Diabetes Drug
- FTC Approves Baxter $625M Claris Buy With Antitrust Fixes
- Abbott Won't Get New Trial After $15M Depakote Verdict
- Doc Charged With Trading Ariad Stock On Wife's Inside Info
- Fed. Circ. Upholds Generics' Win In Abilify Patent Suit
- Ogletree Adds Employment Atty From Morgan Lewis
- Feds Warn Of 'Increasingly Unhinged' Insider Trading Suspect
- Deals Rumor Mill: ADT, Cardinal Health, Adnoc
- WilmerHale Guides $90M IPO For Kala Pharmaceuticals
- Health Data Co. Owner Gets 10 Years For Investor, Tax Frauds
- New E-Cigarette Studies May Prove Key For Litigators
- Catheter Patent Owner Says TC Heartland Can't Sink Suit
- Current Trends In Biologics-Related Inter Partes Reviews
- Unilife Receives Court OK For Sales To Credit Bidders
- FDA Heard All Stories Of AndroGel Heart Attacks, Jury Told
- 5 More AGs Bring Price-Fixing Suit Against Drugmakers
- Shkreli Trial On Hiatus Over Gov't Evidence Gambit
- Major IP Groups Urge Full Fed. Circ. To Eye AIA On-Sale Bar
- DEA Asks DC Circ. To Enact Ban On Opioid Supplier's Sales
- Amphetamine-Laced Supplements Land Florida Exec In Jail
- FDA Policy Analyst Joins Top Generic Drugs Lobby Group
- Surgery Tool Maker Sued Over NJ Woman's Cancer Death
- Fed. Circ. Affirms ITC Infringement Ruling On Dental Patents
- More PTAB Fights Between Big Pharma Could Be Looming
- A Chat With FTC's Thomas Pahl
- Innovating For Wise Juries: Matching Experts
- Shkreli Vowed To Make Trader's Kids Homeless, Jury Hears
- FDA Warning Wire: Donor Screening Lapses At Fertility Clinic
- Teva Employees Say Co. Hid DOJ Antitrust, Bribery Probe
- Sarepta To Pay $35M Plus Royalties In Exondys Patent Dispute
- Consumers Say Merck's Shingles Vaccine Poses Health Risks
- Feds May Appeal 9-Year Sentence In Meningitis Outbreak Case
- HHS Urges More Transparency On 340B Drug Prices
- Ex-FDA Head's Comments May Put Meningitis Cases In Peril
- Atty Stuck With $25K Sanction In Enbrel Discovery Row
- Class Attys Seek $20M In Fees In Merck Pay-For-Delay MDL
- The Rise Of Midsize Firms
- Daubert And Product Liability: Mid-2017 Update — Part 2
- 5 Questions To Ask Yourself Before Submitting Litigation AFA
- Shkreli Investor Irked By Loss, But Then Cashed In Big
- Drug Costs Threaten FDA Quick Approval Program, Docs Say
- Gilead Backs Chancery In Appeal Of $50M Merger Bonus Suit
- Reed Smith Widow Fires Back At GSK Bid For New Trial
- Drug Return Fraudster Fights Forfeiture Bid
- AndroGel Benefits Not Worth Cardiac Risk, Jury Hears
- Venable Adds Ex-Pfizer Lawyer To FDA Practice In DC Office
- RI Atty Must Face Fee Dispute Suit In Texas, Court Affirms
- Gilead Wins $14M In Attys' Fees For Merck Patent Misconduct
- FDA Rejects Amgen Osteoporosis Drug, Asks For Safety Info
- 4 M&A Partners Join Nixon Peabody's New NC Office
- Ex-Fox Rothschild Partner Heads To Generic Drug Co. As GC
- Fed. Circ. Revives Axed Millennium Cancer Drug Patent
- EU Says Teva, Cephalon Deal Violated Antitrust Rules
- How Mobile Apps Can Benefit Your Practice
- J&J Escapes Suit Over Talc-Based Baby Powder
- A More Consistent USPTO Approach To Patent Eligibility
- Daubert And Product Liability: Mid-2017 Update — Part 1
- The Future Of Litigation Finance Is Analytics
- Law360 Names Top Attorneys Under 40
- Retrophin CEO Was Told Of Shady Shkreli Deals, Jury Hears
- AbbVie Needed To Study Heart Impact Of AndroGel, Jury Told
- BCBS Units Sue Insys Over Off-Label Fentanyl Rx Scheme
- Non-Missourians Kicked Out Of Bayer Essure Suit
- 6 Firms To Steer Nearly $1B In IPOs As Deals Perk Up
- Health Hires: Cozen O'Connor, King & Spalding, West Health
- Unilife Committee Says Sale Plan Cuts It Out Of Recovery
- Salk Institute Sued By Top Scientists For Gender Bias
- PTAB Nixes Patent Claims UPenn Said Erbitux Infringed
- Ionis Subsidiary Akcea Therapeutics Prices $125M IPO
- Specific Personal Jurisdiction: The Unanswered Questions
- Lilly Settles Cialis Generic Patent Suit, Cuts Exclusivity
- 'Jury's Still Out' On CRISPR Patent Licensing Pool
- Enough Evidence Tying AndroGel To Heart Attacks, Jury Hears
- FDA Says Lead Blood Test Firm Didn't Report Complaints
- Shkreli Like The Pied Piper, Retrophin CEO Tells Jury
- EU Court Adviser Sides With German Drugmaker In VAT Fight
- Investor Says AMRI's Go-Private Deal Docs Short On Details
- Mylan Can't Move Sanofi's EpiPen Antitrust Suit
- 4 Things To Remember About Refill Reminder Compliance
- Where AI Meets Cybersecurity And The Legal Profession
- Miami Physician Pleads Guilty To Medicare Fraud
- DOJ Arrests 400, Targets Opioids In $1.3B Fraud 'Takedown'
- Why 'Class Action Attorney Fees' Are Such Dirty Words
- 6th Circ. Affirms Class Cert. Denial In Junk Fax Row
- Dr. Reddy's Infringed Horizon's Vimovo Patent, Judge Says
- Shkreli 'Absolutely Stunned' Chairman With Lie
- 3rd Circ. Revives Kidney Disease Treatment Royalties Suit
- Justice Breyer On Changing His Mind And Sparring With Scalia
- Pfizer Assails Janssen Suit Over Remicade Biosimilar
- House Passes Reauthorization Of FDA User Fees
- Stryker Awarded $248M In Post-Halo Patent Remand
- UK Supreme Court Reworks Infringement Test In Eli Lilly Win
- Off-Label Drug Bills Get Little Traction On Capitol Hill
- 'Keurig Of Weed' Suit To Reverse Customs Block Vaporized
- FDA Rejects Ocular Therapeutix Eye Drug
- 3 Takeaways From The FDA Head's New Opioid Rx Standards
- Par Infringed Ferring Colonoscopy Drug IP, Says Del. Judge
- Value-Based Challenges And Opportunities For Pharma Cos.
- Medtronic Case Illustrates High Bar For Inequitable Conduct
- No 'Real Intention To Prosecute' Means Fraudulent Joinder
- Innovating For Wise Juries: Interim Arguments
- Unstructured Data Is Just The Tip Of The Iceberg
- Valeant, Pershing, Investors Battle For Quick Wins In Suit
- Ex-Insys Sales Reps Plead Guilty In Opioid Kickback Scheme
- Justice Breyer On The Limits Of Presidential Power
- CVS Strikes $5M Deal Over Prescription Drug Records
- AIA Sponsor Wants Full Fed. Circ. To Weigh On-Sale Bar Rule
- Shkreli Fund In The Red, Jury Told, As He Boasted Of Millions
- Crucial Expert's Opinion In Doubt For J&J Talc Cancer Trial
- BioScrip Investors Say Chancery Was Wrong To Toss Suit
- Akin Gump Nabs Ex-FDA Deputy Chief
- Judge OKs Settlement In Supplement Co. Junk Fax Row
- $35M Ends US Claims Of Mallinckrodt Link To Opioid Abuse
- FDA Warning Wire: Corroded Equipment At Indian Drug Plant
- FTC Appoints Endo Pay-For-Delay Settlement Monitor
- Walgreens Refutes Customers' Redo Bid In Blood Test Suit
- Momenta Tells Jury Amphastar Ripped Off Drug Patent
- Bayer, J&J Misrepresented Xarelto Risks, Suits Say
- EQT Partners Scoops Up Drug Tech Co. In $850M Deal
- Employees In All But Name: Where's The Privilege?
- LA Leads The Way With Draft Commercial Cannabis Regs
- 5 Questions To Ask Firm Before Accepting A Litigation AFA
- J&J's Talc Supplier Escapes Cancer Trial
- Pulled Pain Pill, Opioid Rates Show Need For Research
- Shkreli's Focus Reminds Investor Of The 'Rain Man'
- McGuireWoods Adds Product Liability Litigator In Dallas
- Ex-FDA Chief Tells Jury AndroGel Ads Were Misleading
- Morgan Lewis Lands Eckert Seamans Atty In Pittsburgh
- Abilify Generics Infringe Otsuka Patent, Fed. Circ. Told
- Unilife Committee Atty Withdraws To Save Firm's Retention
- Bain, Cinven Continue Stada Pursuit With Improved $4.7B Bid
- Ex-Insys Staffer Denied Bid To Use Marijuana Pre-Trial
- Will ACA Repeal Pass? Here's What 11 Experts Think
- Sills Cummis Sues Ex-Client Over Biz Ownership Transfer
- Chocolate Powder Is 'Cocaine On Training Wheels,' FDA Told
- 2 Biotech Cos., Yoga Studio Chain Launch IPOs For $255M
- Novo Gets Sanofi's Insulin Advertising Claims Trimmed
- WaPo Sues DOJ For Opioid Epidemic Docs
- Investors Sue Eye Drug Co. After Manufacturing Issues
- Why Posner Pounced On Eyedrop Class Certification
- Why You Should Argue Your Appeal
- DC Circ. Adds Feather To DEA's Regulatory Authority Hat
- 6 Ways Teaching A Law School Class Can Benefit Lawyers
- Congressional Forecast: July
- Prosthetics Maker Says Shumaker Loop Error Cost It $50M
- Gilead FCA Suit Satisfies Escobar, 9th Circ. Rules
- 6 Shareholder Suits Over Akorn-Fresenius Deal Moved To Ill.
- Teva Targets Ex-Exec Who Dated, Gave Info To Apotex CEO
- Apotex, Ranbaxy End Pay-For-Delay Suit Over Narcolepsy Med
- Bristol-Myers, Pfizer Again Sued Over Eliquis Risks
- Whistleblowers Fight To Keep Medicare Fraud Suit Alive
- Plane Tickets, Voicemails Worry Feds In Insider Trading Case
- Fresenius Asks Judge To Trim Feds' False Claims Suit
- VC-Backed Danish Biotech Zealand Pharma Files $86M US IPO
- Deals Rumor Mill: Elliott Management, Stada, Kind
- Beware Export Controls On Software, Encryption, Technology
- Time To Focus On Cybersecurity In Health Care
- PTAB Nixes AbbVie Patent For $16B Blockbuster Humira
- Ex-Analyst Tells Of 'Depressed' Shkreli After Fund Implosion
- State Classes Get Tag-Team Trials In Syngenta Corn MDL
- Pharmacy Barred From Drug Production Over Contamination
- Generics Lobby Sues To Block Md. Drug Pricing Law
- Konica Minolta To Buy Ambry Genetics In Deal Worth $1B
- Ex-MLB Player Gets Defamation Suit Sent To NY State Court
- AbbVie Tells Jury Studies Don't Tie AndroGel To Heart Attacks
- 8th Circ. Upholds DePuy Quick Win In Hip Implant Suit
- Actavis Reaches Deal With Vivus Over Obesity Drug Patents
- Lawsuit Challenges Fla. Medical Marijuana Smoking Ban
- EU Accuses GE, Others Of Filing Misleading Info On Mergers
- Namenda Wholesalers Fire Back At Teva's Bid To DQ Expert
- Precision Biologics Investor Sues For Custodian, Recovery
- GSK Says Patent Deal Relevant To Abbott HIV Drug Suit
- Sherwin-Williams, Others Look To Dodge Landfill Cleanup Suit
- Covington Snags Undefeated Litigator From O'Melveny
- Bowing To FDA, Endo Halts Opana Painkiller Sales
- Merck's Noxafil Wasn't Revealed Before Invention, Court Told
- FDA Halts 3 Merck Keytruda Studies After Deaths
- Considerations For Entry Into The Marijuana Industry
- Robbins Geller, Johnson & Weaver To Helm Cempra Suit
- Illinois County Sues Drug Cos. Over Role In Opioid Crisis
- Talc Supplier Likely Can't Escape J&J Cancer Trial
- Justice Stevens On Gorsuch And Sticking With The Cubs
- Unilife Creditor Objects To Committee's Counsel Retention
- Shkreli Ordered To Shut Up About Securities Fraud Trial
- AbbVie Sold AndroGel Without Heart Risk Warning, Jury Told
- Feds Fight Ex-MLB Player's Bid For New Insider Trading Trial
- Valeant, Pershing Trying To Hide Behind SEC, Investors Say
- HQ's Heart-Drug Generic Would Flout Baxter Deal, Judge Says
- Venture-Backed Dermatology Co. Files $75M IPO
- Umberg Zipser Boosts IP Group With 2 From Fish & Tsang
- Fed. Circ. Asked To Rehear Patent On-Sale Bar Case En Banc
- FDA Warning Wire: Drugmaker Defiance, Dangerous Dog Food
- Hatch Floats Bill Promoting Rare Disease Treatments
- FDA May Push Boundaries To Speed REMS Negotiations
- Chinese Vaccine Co. Investors Sue After Bribery Report
- Innovating For Wise Juries: Openings Before Voir Dire
- 5 Questions To Ask Client Before Proposing A Litigation AFA
- Justice Stevens On Playing Politics With The High Court
- J&J's McNeil Gets New Trial After $48M Motrin Reaction Loss
- DLA Piper Strengthens Corporate Practice With Cooley Atty
- UnitedHealth Members Fight Bid To Toss Clawback Suit
- Spokeo Doesn't Doom Genetic Privacy Row, Judge Says
- Drugmakers Urge FDA To Phase Out Older Opioids
- Pa. Judge Urged To Move Mesh Cases After Justices' Rulings
- Theranos Wants Class Limited To Indirect Share Purchasers
- Redfin, Clementia Eyeing A Combined $215M In IPOs
- OvaScience Shareholder Attacks Director Compensation Deal
- Bartlit Beck Scores A Trio Of Patent Trial Verdicts
- Fla. Compounding Pharmacy Ripped Off Tricare, Feds Claim
- Teva Wants Ex-Exec DQ'd As Expert In Namenda Buyers' Suit
- A Regulatory Bellwether: Forecasting Cyber Breach Litigation
- Tech, Pharma Divided Over Section 101 Challenges Post-Alice
- Leegin's 10-Year Checkup